-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target

Benzinga·07/15/2026 17:20:01
语音播报
BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $34 price target.